A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Mocetinostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Sponsors MethylGene; Mirati Therapeutics
- 03 Jun 2013 Data were presented at the 2013 ASCO Annual Meeting, according to a MethylGene media release.
- 01 Feb 2012 Actual patient number (74) added as reported by ClinicalTrials.gov.
- 01 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.